Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins

Current Opinion in Lipidology

Volumn 5, Issue 1, 1994, Pages 48-58

  Seed, Mary ^a   Crook, David ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ESTROGEN; GESTAGEN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BONE ATROPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; PARTICLE SIZE; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

EID: 0028058018     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199402000-00009     Document Type: Review

References (81)

1. WHITEHEAD MI, HILLARD TC, CROOK D: The Role and Use of Progestogens. Obstet Gynecol 1990, 75(suppl).59-76.
2. HJORTLAND MC, MCNAMARA PM, KANNEL WB: Some Atherogenic Concomitants of Menopause: The Framingham Study. Am J Epidemiol 1976, 106:304-311.
3. MATTHEWS KA, MEILAHN E, KULLER LH, KELSEY SF, CAGGIULA AW, WING RR: Menopause and Risk Factors for Coronary Heart Disease. N Engl J Med 1989, 321:641-646.
4. RAZAY G, HEATON KW, BOLTON CH: Coronary Heart Disease Risk Factors in Relation to Menopause. Q J Med 1992, 85:307-308.
5. JENSEN J, NILAS L, CHRISTIANSEN C: Influence of Menopause on Serum Lipids and Lipoproteins. Maturitas 1990, 12:321-331
6. STEVENSON JC, CROOK D, GODSLAND IF: Effects of Age and Menopause on Lipid Metabolism in Healthy Women. Atherosclerosis 1993, 98:83-90. A cross-sectional study in which the authors demonstrate menopause-induced reductions in HDL2 cholesterol and increases in triglycerides and LDL cholesterol, independent of ageing.
7. CROOK D, SEED M: Endocrine Control of Plasma Lipoprotein Metabolism: Effects of Gonadal Steroids. Baillière's Clin Endocrinol Metab 1990, 4:851-876.
8. SEED M: Sex Hormones, Lipoproteins, and Cardiovascular Risk. Atherosclerosis 1991, 90:1-7.
9. LOBO RA: Effects of Hormonal Replacement on Lipids and Lipoproteins in Postmenopausal Women. J Clin Endocrinol Metab 1991, 73:925-930.
10. CROOK D: Postmenopausal Oestrogens and Progestogens: Effects on Plasma lipoprotein Risk Markers for Coronary Heart Disease. In Progress in Reproductive Medicine. Edited by Asch R, Studd JWW. Lancashire: Parthenon; 1993:261-72. A detailed review of the effects of hormone replacement therapy on serum lipoproteins.
11. NABULSI AA, FOLSOM AR, WHITE A, PATSCH W, HEISS G, WU KK, SZKLO M: Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women. N Engl J Med 1993, 328:1069-1075. Data from the Atherosclerosis Risk in Community study show that both oestrogen and oestrogen-progestogen therapies can have beneficial effects on risk markers for coronary heart disease.
12. CROOK D, STEVENSON JC: Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women [Letter]. N Engl J Med 1993, 329:1041-1042.
13. SIDDLE NC, JESINGER DK, WHITEHEAD MI, TURNER P, LEWIS B, PRESCOTT P: Effect on Plasma Lipids and Lipoproteins of Postmenopausal Oestrogen Therapy with Added Dydrogesterone. Br J Obstet Gynaecol 1990, 97:1093-1100.
14. VAN DER MOOREN MJ, DEMACKER PNM, THOMAS CMG, ROLLAND R: Beneficial Effect on Serum Lipoproteins by 17-Oestradiol-Dydrogesterone Therapy in Postmenopausal Women: A Prospective Study. Eur J Obstet Gynecol Reprod Biol 1992, 47:153-160. A clinical trial of hormone replacement therapy with dydrogesterone, a spatial isomer of natural progesterone, with analysis of lipids and apolipoproteins.
15. CASTELLI WP: The Triglyceride Issue: A View from Framingham. Am Heart J 1986, 112:432-437.
16. CROOK D, GODSLAND IF, WORTHINGTON M, FELTON C, PROUDLER AJ, STEVENSON JC: A Comparative Metabolic Study of Two Low Estrogen Dose Oral Contraceptives Containing Gestodene or Desogestrel Progestins. Am J Obstet Gynecol 1993, 169:1183-1189.
17. SAURE A, HIRVONEN E, TIKKANEN MJ, VIINIKKA A, YLIKORKALA O: A Novel Oestradiol-Desogestrel Preparation for Hormone Replacement Therapy: Effects on Hormones, Lipids, Bone, Climacteric Symptoms and Endometrium. Maturitas 1993, 16:1-12. A clinical trial of hormone replacement therapy containing desogestrel as progestogen. HDL was unaffected, implying that desogestrel can oppose the ability of postmenopausal oestrogen to increase HDL.
18. CROOK D, CUST MP, GANGAR KF, WORTHINGTON M, HILLARD TC, STEVENSON JC, WHITEHEAD MI, WYNN V: Comparison of Transdermal and Oral Estrogen/Progestin Hormone Replacement Therapy: Effects on Serum Lipids and Lipoproteins. Am J Obstet Gynecol 1992, 166:950-955.
19. MATTSSON LA, SAMSOIE G, VON SCHOULTZ B, UVEBRANT A, WIKLUND I: Transdermally Administered Oestradiol Combined with Oral Medroxyprogesterone Acetate: The Effects on Lipoprotein Metabolism in Postmenopausal Women. Br J Obstet Gynaecol 1993, 100:450-453. Confirmation that non-oral hormone replacement therapy can lower triglyceride concentrations.
20. METKA M, HANES V, HEYIMANEK G: Hormone Replacement Therapy: Lipid Responses to Continuous Combined Oestrogen and Progestogen versus Oestrogen Monotherapy. Maturitas 1992, 15:53-59.
21. MARSH MS, CROOK D, ELLERINGTON MC, WHTICROFT SI, WHITEHEAD MI, STEVENSON JC: Effect of Continuous Combined Estrogen Replacement Therapy on Serum Lipids and Lipoproteins. Obstet Gynecol in press.
22. MEUSING RA, MILLER VT, LA ROSA JC, STOY DB, PHILLIS EA: Effects of Unopposed Conjugated Equine Estrogen on Lipoprotein Composition and Apolipoprotein-E Distribution. J Clin Endocrinol Metab 1992, 75:1250-1254. Lipoprotein compositional studies in postmenopausal women given oestrogen. This study emphasizes that hormone replacement therapy induces major changes in the distribution of lipids and apolipopro-teins through the lipoprotein spectrum.
23. PHAIR RD, APPLEBAUM-BOWDEN D, ABROI, R, COLVIN PL, ETTINGER WH, HAZZARD WR: Modulation by Hstrogen of Plasma Lipoprotein Apolipoprotein B Kinetics In Postmenopausal Women. 62nd EAS Congress, 1993:123.
24. BARR DP, Russ EM, EDER HA: Protein Lipid Relationships in Human Plasma. Am J Med 1951, 11:480-493.
25. BARR DP, Russ EM, EDER HA: Influence of Estrogen on Lipoproteins in Atherosclerosis. Trans Assoc Am Phys 1952, 65:102-111.
26. CORONARY DRUG RESEARCH GROUP: The Coronary Drug Project: Initial Findings Leading to Modification of its Research Protocol. JAMA 1970, 214:1303-1313.
27. FURMAN RH, HOWARD RP, NORCIA LN, KEATY EC: The Influence of Androgens, Estrogens and Related Steroids on Serum Lipids and Lipoproteins. Am J Med 1958, 24:80-97.
28. TIKKANKN MJ, NIKKILA EA, VARTIAINEN E: Natural Oestrogen as an Effective Treatment for Type II Hyperlipoproteinaemia in Post Menopausal Women. Lancet 1978, 2:490-492.
29. SEED M: Oral Contraception, Hormone Replacement Therapy and Hyperlipidaemia. Postgrad Med J 1992, 68:877-879.
30. GRANFONE A, CAMPOS H, MCNAMARA JU, SCHAFFER MM, LAMON-FAVA S, ORDOVAS JM, SCHAEFER EJ: Effects of Estrogen Replacement on Plasma Lipoproteins and Apolipoproteins in Post Menopausal, Dyslipidaeinic Women. Metabolism 1992, 41:1193-1198. A heterogeneous group of subjects; however, hormone replacement therapy is at last used for treatment of dyslipidaemia.
31. EXPERT PANEL ON DETECTION, EVALUATION AND TREATMEEN OF HIGH BLOOD CHOLESTEROL IN ADULTS: Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993, 269:3015-3023.
32. BUSH TL, BARRETT-CONNOR E, COWAN LD, CRIQUI MH, WALLACE RB, SUCHINDRAN CM, TYROLER HA, RIFKIND BM: Cardiovascular Mortality and Non Contraceptive Use of Estrogen in Women: Results from the Lipid Research Clinics Program Follow-Up Study. Circulation 1987, 75:1102-1109.
33. WALSH BW: Estrogen Replacement and Heart Disease. Clin Obstet Gynecol 1992, 35:894-899. Succinct and positive review of the cardiovascular benefits of hormone replacement therapy.
34. MEADE TW, BERRA A: Hormone Replacement Therapy and Cardiovascular Disease. Br Med Bull 1992,48:276-308. Review of the literature with special emphasis on thrombosis risk factors. The authors propose a randomized controlled trial of the cardiovascular benefits of hormone replacement therapy.
35. KHAW KT: The Menopause and Hormone Replacement Therapy. Postgrad Med J 1992, 68:615-623.
36. LA ROSA JC: Women, Lipoproteins and Cardiovascular Disease Risk. Int J Fertil 1992, 37:67-71. A first description of the aims of the Prospective Estrogen Progestin Intervention study.
37. LOBO RA: The Role of Progestins in Hormone Replacement Therapy. Am J Obstet Gynecol 1992, 166:1997-2004.
38. COLDITZ GA, STAMPFER MJ: Cardiovascular Effects of Menopause and Estrogen Replacement: The Epidemiological Evidence. In Hormone Replacement Therapy. Edited by Swartz D. Baltimore: Williams and Wilkins; 1992:109-137. An excellent summary of the evidence from many trials of hormone replacement therapy.
39. STAMPFER MJ, COLDITZ GA: Estrogen Replacement Therapy and Coronary Heart Disease: A Quantitative Assessment of the Epidemiologic Evidence. Prev Med 1991, 20:47-63.
40. WILSON PW, GARRISON RJ, CASTELLI WP: Postmenopausal Oestrogen Use, Cigarette Smoking and Cardiovascular Morbidity in Women over 50: The Framingham Study. N Engl J Med 1985, 313:1044-1049.
41. EGELAND GM, KULLKR LH, MATTHEWS KA, KELSEY SF, CAYLEY J, GUZICK D: Premenopausal Determinants of Menopausal Estrogen Use. Prev Med 1991, 20:343-349.
42. FALKEBORN M, PERSSON I, ADAMI H, BERGSTROM R, EAKER E, MOHSEN HLR, NAESSEN T: The Risk of Acute Myocardial Infarction after Oestrogen-Progestogen Replacement. Br J Obstet Gynaecol 1992, 99:821-828. A retrospective survey of hormone use and myocardial infarction, with no deleterious effect found on coronary heart disease with the addition of progestogen to oestrogen in hormone replacement therapy.
43. GRUCHOW HW, ANDERSON AJ, BARBORIAK JJ, SOBOCINSKI KA: Post Menopausal Use of Oestrogen and Occlusion of Coronary Arteries. Am Heart J 1988, 115:954-963.
44. MCFARLAND KF, BONIFACE ME, HOKNUNG CA, EARNHARDT W, O'NEAL HUMPHRIES J: Risk Factors and Non Contraceptive Oestrogen Use in Women With and Without Coronary Disease. Am Heart J 1989, 117:1209-1214.
45. SULLIVAN JM, VAN DER ZWAAG R, HUGHES JP, MADDOCK V, CROETZ FW, RAMANATHAN KB, MIRVIS DM: Estrogen Replacement and Coronary Heart Disease: Effect of Survival in Post Menopausal Women. Arch Intern Med 1990, 150:2557-2562.
46. SULLIVAN JM, VAN DER ZWAAG R, HUGHES JP: Post Menopausal Estrogen Use and Coronary Atherosclerosis. Ann Intern Med 1988, 108:258-263.
47. HONG MK, ROMM PA, REAGAN K, GREEN CE, RACKLEY CE: Effects of Estrogen Replacement Therapy and Serum Lipid Values and Angiographically Defined Coronary Artery Disease in Post Menopausal Women. Am J Cardiol 1992, 69:176-178.
48. ROSANO GMC, SARREL PM, POOLE-WILSON PA, COLLINS P: Beneficial Effect of Oestrogen on Exercise Induced Myocardial Ischaemia in Women with Coronary Artery Disease. Lancet 1993, 342:133-136. Innovative clinical study showing that acute administration of oestrogen can reduce myocardial ischaemia.
49. WAGNER JD, ST CLAIR RW, SCHWENKLE DC, SHIVELY CA, ADAMS MR, CLARKSON TB: Regional Differences in Arterial Low Density Lipoprotein Metabolism in Surgically Postmenopausal Cynomolgus Monkeys. Arterioscler Thromb 1992, 12:717-725. Exciting tracer studies showing that oestrogens affect the ability of the arterial wall to take up oestrogen.
50. HAMM TE, KAPLAN JR, CLARKSON TB, BULLOCK EC: Effects of Gender and Social Behaviour on the Development of Coronary Atherosclerosis in Cynomolgus Monkeys. Atherosclerosis 1983, 48:221-233.
51. ADAMS MR, CLARKSON TB, KAPLAN JR, KORITNIK DR: Ovariectomy, Social Status and Coronary Atherosclerosis in Cynomolgus Monkeys. Arteriosclerosis 1985, 5:193-200.
52. ADAMS MR, CLARKSON TB, KAPLAN JR, KORITNIK DR: Pregnancy Associated Inhibition of Coronary Artery Atherosclerosis in Monkeys: Evidence of a Relationship with Endogenous Estrogen. Arteriosclerosis 1987, 7:378-384.
53. ADAMS MR, KAPLAN JR, MANUCK SB, KORITNIK DR, PARKS JS, WOLFE MS, CLARKSON TB: Inhibition of Coronary Artery Atherosclerosis by 17 Beta-Oestradiol in Ovariectomized Monkeys. Lack of an Effect of Added Progesterone. Arteriosclerosis 1990, 10:1051-1057.
54. WILLIAMS JK, ADAMS MR, HERRINGTON DM, KLOPFERSTEIN HS: Estrogen Modulates Responses of Atherosclerotic Coronary Arteries. Circulation 1990, 81:1680-1687.
55. WILLIAMS JK, ADAMS MR, HERRINGTON DM, CLARKSON TB: Short Term Administration of Estrogen and Vascular Responses of Atherosclerotic Coronary Arteries. J Am Coll Cardiol 1992, 20:452-457. Experimental angiography studies showing that the typical response of atherosclerotic coronary arteries to acetylcholine is leversed by acute administration of oestrogen.
56. BING RJ, COMFORTO A: Reversal of Acetylcholine Effect on Atherosclerotic Coronary Arteries by Oestrogen: Pharmacologic Phenomenon of Clinical Importance. J Am Coll Cardiol 1992, 20:458-459.
57. TIKKANEN MJ: Mechanisms of Cardiovascular Protection by Post Menopausal Hormone Replacement Therapy. Cardiovascular Risk Factors 1993, 3:138-143. A superb account of non-lipoprotein-mediated mechanisms through which hormone replacement therapy may alter coronary heart disease incidents.
58. ••] of non-lipoprotein-mediated mechanisms.
59. GANGAR KF, REID BA, CROOK D, HILLARD TC, WHTTEHEAD MI: Oestrogens and Atherosclerotic Vascular Disease: Local Vascular Factors. Baillière's Clin Endocrinol Metab 1993, 7:47-60. A detailed, illustrated review of oestrogens and atherosclerosis, in which techniques for investigation are discussed.
60. KRAUSS RM: The Tangled Web of Coronary Risk Factors. Am J Med 1991, 90:36S-41S.
61. TRIBBLE DL, HOLL LG, WOOD PD, KRAUSS RM: Variations in Oxidative Susceptibility among Six Low-Density Lipoprotein Subfractions of Differing Density and Particle Size. Atherosclerosis 1992, 93:189-199.
62. HUBER LA, SCHEFLLER E, POLL T, ZEIGLER R, DRESEL HA: 17b-Oestradiol Inhibits LDL Oxidation and Cholesterol Ester Formation in Cultured Macrophages. Free Rad Res Commun 1990, 8:167-173.
63. SOMA M, FUMAGALLI R, PAOLETTI R, MESCHIA M, CARENA MAINI M, CROSIGNANI P, GHANEM K, GAUBATZ J, MORRISETT JD: Plasma Lp(a) Concentration after Oestrogen and Progestogen in Postmenopausal Women [Letter]. Lancet 1991, 337:612.
64. SEED M, O'CONNOR V, PEROMBELON N, O'DONNELL M, REAVELEY D, KNIGHT BL: The Effect of Nicotinic Acid and Acipimox on Lipoprotein(a) Concentration and Turnover. Atherosclerosis 1993, 101:61-68.
65. SOMA M, OSNAGO-GADDA I, PAOLETTI R, FUMAGALLI R, MORRISETT JD, MESCHIA M, CROSIGNANI P: The Lowering of Lipoprotein(a) Induced by Estrogen plus Progesterone Replacement Therapy in Postmenopausal Women. Arch Intern Med 1993, 153:1462-1468. Further details of the study first mentioned in a letter to the LANCET in 1991 [64], The first demonstration of the ability of hormone replacement therapy to reduce lipoprotein (a) concentrations.
66. MEUSING RA, MILLER VT, MILLS TL, LA ROSA JC: Effects of Postmenopausal Unopposed Estrogen and Combined Therapy on lipoprotein(a) Levels. Arterioscler Thromb 1991, 11:1452.
67. ALBERS JJ, TAGGART HM, APPLEDAUM-BOWDEN D, HAFFNER S, CHESNUT CH, HAZZARD WR: Reduction of Lecithin-Cholesterol Acyltransferase, Apolipoprotein D and the Lp(a) Lipoprotein with the Anabolic Steroid Stanozolol. Biochim Biophys Acta 1984, 795:293-296.
68. CROOK D, SIDHU M, SEED M, O'DONNEU M, STEVENSON JC: Lp(a) Levels in Women given Danazol, an Impeded Androgen Atherosclerosis 1992, 92:41-47. A demonstration of striking reduction in hpoprotein (a) concentration in women who were given the impeded androgen danazol. Mechanisms behind this effect remain unclear.
69. RYMER J, CROOK D, SIDHU M, CHAPMAN M, STEVENSON JC: Effects of Tibolone on Serum Concentrations of Lipoprotein(a) in Postmenopausal Women. Acta Endocrinol (Copenh) 1993, 128:259-262.
70. FARISH E, ROLTON HA, BARNES JF, HART DM: Lipoprotein(a) Concentrations in Postmenopausal Women taking Norethisterone. BMJ 1991, 303:694.
71. HENRIKSSON P, ANGELIN B, BERGLUND L: Hormonal Regulation of Serum Lp(a) Levels. J Clin Invest 1992, 89:1166-1171. This study shows dramatic lowering of lipoprotein (a) by massive closes of oestrogen in men with prostatic cancer.
72. ZECHNER R, DESOIE G, SCHWEDITSCH MO, PFEIFFER KP, KOSTNER GM: Fluctuations of Plasma Lipoprotein(a) Concentrations during Pregnancy and Post Parturition. Metabolism 1986, 35.333-336.
73. SEED M, DOHERTY E, O'CONNOR B, REAVELEY D: Effect of High Endogenous Oestradiol on Lipoprotein Concentrations. J Endocrinol 1991, 131:73.
74. MEILAHN EN, KULLER LH, MATTHEWS KA, STEIN A: Lp(a) Concentrations among Pre- and Postmenopausal Women over Time: The Healthy Women Study. Circulation 1991, 84(suppl II):546.
75. HEINRICH J, SANDKAMP M, KOKOTT R, SCHULTE H, ASSMANN G: Relationship of Lipoprotein(a) to Variables of Coagulation and Fibrinolysis in a Healthy Population. Clin Chem 1991, 37:1950-1954.
76. JENNER JL, ORDOVAS JM, LAMON-FAVA S, SCHAEFER MM, WILSON PWF, CASTELLI WP, SCHAEFER EJ: Effects of Age, Sex, and Menopausal Status on Plasma Lipoprotein(a) Levels. Circulation 1993, 87:1135-1141.
77. LOBO RA, NOTELOVITZ M, BERNSTEIN L, KHAN FY, ROSS RK, PAUL WL: Lp(a) Lipoprotein: Relationship to Cardiovascular Disease Risk Factors, Exercise, and Estrogen. Am J Obstet Gynecol 1992, 166:1182-1190.
78. BHATNAGAR D, DURRINGTON PN: Does Measurement of Apolipoproteins Add to the Clinical Diagnosis and Management of the Dyslipidemias. Curr Opin Lipidol 1993, 4:299-304. Important critique of the current standards of lipoprotein (a) research.
79. SEED M, HOPPLICHER F, REAVELEY D, MCCARTHY S, THOMPSON GR, BOERWINCKLE E, UTERMANN G: Relation of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Artery Disease in Familial Hypercholesterolaemia. N Engl J Med 1990, 322:1494-1499.
80. MARTIN KA, FREEMAN MW: Postmenopausal Hormone-Replacement Therapy. N Engl J Med 1993, 328:1115-1117.
81. UTERMANN G: The Mysteries of Lipoprotein(a). Science 1989, 264:904-910.